Solid tumors: Target antigens for treatment

Initially developed to treat hematological malignancies, CAR-T therapy is currently being expanded to treat solid tumors by employing specialized CAR-T cells that attack specific antigens. Clinical trials are now underway to assess the efficacy of CAR-T cells that target GPC3, FAP, L1CAM, HER2, MSLN, CEACAM5, IL-13RA2, EpCAM, PSMA, and EGFR.

Third-generation HER2 CAR-T cells have been shown in studies to remove glioblastoma cells successfully, and their efficacy can be increased by combining them with PD-1 and CTLA-4 blockade.

Learn More About The Reagents and services

Cytokines, such as IL4, TGF-beta, IL-2, IL-7, IL-10, IL-12, and IL-15, have also been linked to the therapeutic effects of CAR-T therapy. Sino Biological offers a wide range of reagents and services to aid in developing CAR-T treatments for solid tumors.

Figure 1. CAR-T recognizes target antigens and kills tumor cells. Image Credit: Sino Biological Inc.

Featured recombinant proteins

Sino Biological provides high-quality recombinant proteins to aid in developing CAR-T treatments for solid tumors.

• High-purity
• Activity-validated
• Low-endotoxin
• Cited by researchers

Human EGFR protein Cat#: 10001-H08H. HPLC verified

Purity: >90% as determined by HPLC. Image Credit: Sino Biological Inc.

Immobilized human EGF protein (Cat#: 10605-H01H) can bind human EGFR protein.

Human IL13RA2 protein Cat#: 10350-H08H-B

Immobilized human IL13 protein (Cat#: 10369-H01H) can bind human IL13RA2 protein. Image Credit: Sino Biological Inc.

Human HER2/ERBB2 protein Cat#: 10004-H08H. HPLC verified

Ability to block anti-HER2 mediated inhibition of BT474 human breast ductal carcinoma cell proliferation. Image Credit: Sino Biological Inc.

Immobilized human HER2/ERBB2 protein can bind Anti-HER2 antibody (Trastuzumab). Image Credit: Sino Biological Inc.

Human GPC3 protein Cat#: 10088-H08H 8 Citations

Immobilized human GPC3 protein can bind to human bFGF/FGF2 protein. Image Credit: Sino Biological Inc.

More recombinant proteins (partial)

Table 1. Source: Sino Biological Inc.

Featured antibodies for target antigens

Sino Biological has created a panel of antibodies for cell therapy research in solid tumors, including IHC-P, ELISA, IP, FCM, and WB.

Anti-EpCAM antibody (Cat#: 10694-R028)

• Type: Rabbit MAb
• Ig Type: Rabbit IgG
• Applications: WB, ELISA, IHC-P, FCM, ICC/IF, IP

Immunochemical staining of human EpCAM in human bladder carcinoma. Image Credit: Sino Biological Inc.

Anti-L1CAM antibody (Cat#: 10140-R014)

• Type: Rabbit MAb
• Ig Type: Rabbit IgG
• Applications: ELISA (Det), IHC-P, FCM, ICC/IF

Flow cytometric analysis of human CD171 expression on HeLa cells. Image Credit: Sino Biological Inc.

Anti-EGFR antibody (Cat#: 10001-R021)

• Type: Rabbit MAb
• Ig Type: Rabbit IgG
• Applications: ELISA, ELISA (Det), ICC/IF

Immunofluorescence staining of Human EGFR in A431 cells. Image Credit: Sino Biological Inc.

Anti-CEACAM5 antibody (Cat#: 11077-R327)

• Type: Rabbit MAb
• Ig Type: Rabbit IgG
• Applications: IHC-P

Immunochemical staining of human CEACAM5 in human colon carcinoma. Image Credit: Sino Biological Inc.

More antibodies for target antigens (partial)

Table 2. Source: Sino Biological Inc.

Cell therapy-related cytokines

• TGF-β
• IL2
• IL4
• IL7
• IL12
• IL15